HC Wainwright Forecasts Pelthos Therapeutics Q2 Earnings

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Equities research analysts at HC Wainwright cut their Q2 2026 EPS estimates for Pelthos Therapeutics in a note issued to investors on Friday, May 15th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($4.19) per share for the quarter, down from their prior estimate of ($3.48). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pelthos Therapeutics’ current full-year earnings is ($11.35) per share. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q3 2026 earnings at ($3.27) EPS, Q4 2026 earnings at ($3.62) EPS, FY2026 earnings at ($16.43) EPS, FY2027 earnings at ($5.09) EPS, FY2028 earnings at $5.97 EPS, FY2029 earnings at $10.32 EPS and FY2030 earnings at $13.50 EPS.

PTHS has been the subject of several other reports. Cantor Fitzgerald assumed coverage on shares of Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price objective for the company. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Roth Mkm cut their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Oppenheimer upped their price target on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday. Finally, Piper Sandler started coverage on shares of Pelthos Therapeutics in a report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.80.

Pelthos Therapeutics Stock Down 2.1%

PTHS opened at $26.15 on Tuesday. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. Pelthos Therapeutics has a 52-week low of $9.00 and a 52-week high of $54.29. The stock’s 50 day simple moving average is $23.61. The stock has a market capitalization of $91.00 million, a P/E ratio of -1.27 and a beta of 3.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The company had revenue of $10.91 million for the quarter.

Institutional Trading of Pelthos Therapeutics

Large investors have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in shares of Pelthos Therapeutics in the 4th quarter worth about $343,000. Pale Fire Capital SE grew its position in Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after buying an additional 4,819 shares in the last quarter. Knott David M Jr grew its position in Pelthos Therapeutics by 9.3% in the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after buying an additional 1,792 shares in the last quarter. Persistent Asset Partners Ltd boosted its position in shares of Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after purchasing an additional 3,295 shares in the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).